Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 67.50
Bid: 65.00
Ask: 70.00
Change: 1.00 (1.50%)
Spread: 5.00 (7.692%)
Open: 66.50
High: 67.50
Low: 66.50
Prev. Close: 66.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of Half Yearly Report

17 Sep 2014 14:00

RNS Number : 9340R
NetScientific PLC
17 September 2014
 



 

 

 

 

 

 

NetScientific plc

('NetScientific' or 'the Company')

 

 Notification of Half Yearly Report Date

 

 

NetScientific (AIM: NSCI), the biomedical and healthcare technology investment group, will announce its half yearly report for the six months ended 30 June 2014 on Tuesday, 23 September 2014.

 

A presentation for analysts will be held at 11.30am on Tuesday 23 September 2014 at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ.

- Ends -

About NetScientific

NetScientific is a healthcare and life sciences company with a global reach that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.

 

For more information, please visit the website at www.netscientific.net.

 

 

Contact Details

 

NetScientific plc

Tel: +44 (0) 20 3290 8877

Farad Azima, CEO

Peter Thoms, CFO

Liberum (NOMAD and Broker)

Tel: +44 (0)20 3100 2000 end_of_the_skype_highlighting

Chris Bowman / Christopher Britton / Thomas Bective

Instinctif Partners

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Tim Watson

Email: netscientific@instinctif.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORLDLFFZKFFBBD
Date   Source Headline
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 20227:00 amRNSBoard Change
7th Nov 20223:40 pmRNSPDS reports presentation of data at cancer society
20th Oct 20227:00 amRNSEMV Capital secures investment in Ventive
11th Oct 20224:00 pmRNSPDS Update
3rd Oct 20221:56 pmRNSPDS completes End-of-Phase 2 meeting with FDA
30th Sep 20227:00 amRNSHalf-year Report
25th Aug 20227:00 amRNSPDS Completes $35 Million Financing Agreement
16th Aug 20227:00 amRNSAcquisition of 30% Vortex stake & new Vortex CEO
8th Aug 20224:45 pmRNSPDS Reports Q2 2022 Results & Business Update
29th Jun 20222:05 pmRNSResult of AGM
28th Jun 20229:15 amRNSHolding(s) in Company
27th Jun 20228:30 amRNSDirector/PDMR Shareholding
27th Jun 20228:30 amRNSHolding(s) in Company
22nd Jun 20227:00 amRNSResult of Placing and Total Voting Rights
21st Jun 20224:41 pmRNSProposed Placing to raise at least £1.5 million
17th Jun 202212:00 pmRNSNetScientific to increase Q-Bot stake to 23.7%
15th Jun 20227:00 amRNSQ-Bot secures £1.6m of investment to fund growth
7th Jun 202211:07 amRNSNotice of AGM and Annual Report & Accounts
6th Jun 20227:00 amRNSPDS Granted FDA Fast Track Designation for PDS0101
27th May 20222:39 pmRNSPDS Biotech - new data for ongoing clinical trials
19th May 20227:00 amRNSGeneral Counsel Strategic Hire & Grant of Options
16th May 20227:00 amRNSProAxsis Update
12th May 20227:00 amRNSFinal Results
11th May 20223:46 pmRNSPDS Reports Q1 2022 Results & Business Update
9th May 20227:00 amRNSNotice of Results & Investor Presentation
6th May 20227:00 amRNSAcquisition of 30% of Vortex Biotech Holdings
25th Apr 20222:05 pmRNSSecond Price Monitoring Extn
25th Apr 20222:00 pmRNSPrice Monitoring Extension
25th Apr 202211:05 amRNSSecond Price Monitoring Extn
25th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 20221:24 pmRNSPDS Provides Business Update & Full-Year Results
4th Mar 20227:30 amRNSPublication of Shareholder Newsletter
24th Feb 20224:45 pmRNSPDS Announces Preliminary Safety Data on PDS0101
15th Feb 20222:32 pmRNSPDS Clinical Trial with Mayo Clinic
2nd Feb 20223:00 pmRNSPDS Phase 2 Trial Update
28th Jan 20228:45 amRNSPDS Announces Preclinical Data for PDS0202 Vaccine
18th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20222:20 pmRNSPDS Granted Novel HPV16 Immunotherapy Patent
10th Jan 20227:00 amRNSProAxsis CEO End of Year Update
29th Dec 20218:47 amRNSIssue of Equity
21st Dec 20211:59 pmRNSTR-1: Form for notification of major holdings
21st Dec 20217:00 amRNSQ-Bot Investment and Share Acquisition
20th Dec 20217:00 amRNSAcquisition of majority stake in Cetromed
13th Dec 20217:00 amRNSMartlet Capital Update
6th Dec 20212:53 pmRNSPDS Phase 2 Clinical Trial Update
26th Nov 20217:00 amRNS$1million investment in portfolio company, EpiBone

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.